6,875 Shares in Axon Enterprise, Inc $AXON Acquired by B. Metzler seel. Sohn & Co. AG

B. Metzler seel. Sohn & Co. AG purchased a new position in Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,875 shares of the biotechnology company’s stock, valued at approximately $3,854,000.

A number of other hedge funds have also recently added to or reduced their stakes in AXON. Rockefeller Capital Management L.P. boosted its holdings in Axon Enterprise by 53.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 11,518 shares of the biotechnology company’s stock worth $6,542,000 after acquiring an additional 4,002 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Axon Enterprise by 1.3% in the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after purchasing an additional 5,419 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Axon Enterprise in the fourth quarter valued at about $13,116,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Axon Enterprise during the first quarter valued at about $15,067,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Axon Enterprise by 40.7% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 15,083 shares of the biotechnology company’s stock valued at $6,406,000 after purchasing an additional 4,360 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AXON. Citizens Jmp reaffirmed a “market outperform” rating and issued a $700.00 price objective on shares of Axon Enterprise in a research report on Thursday, June 25th. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Wednesday, August 5th. JPMorgan Chase & Co. upped their target price on Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Needham & Company LLC reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Thursday, August 6th. Finally, UBS Group lifted their price target on Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $730.92.

Axon Enterprise Stock Up 2.2%

Shares of NASDAQ AXON opened at $627.75 on Friday. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $794.29. The business has a 50-day simple moving average of $543.11 and a two-hundred day simple moving average of $476.87. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47. The company has a market cap of $51.00 billion, a P/E ratio of 260.48, a P/E/G ratio of 9.97 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm had revenue of $904.39 million for the quarter, compared to the consensus estimate of $876.42 million. During the same period in the prior year, the firm posted $2.12 earnings per share. The company’s revenue for the quarter was up 35.3% on a year-over-year basis. Research analysts anticipate that Axon Enterprise, Inc will post 2.04 earnings per share for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 20,000 shares of Axon Enterprise stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the chief executive officer directly owned 3,060,997 shares in the company, valued at $1,530,498,500. The trade was a 0.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeri Williams sold 629 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $469.64, for a total value of $295,403.56. Following the sale, the director owned 1,141 shares in the company, valued at $535,859.24. The trade was a 35.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 66,989 shares of company stock valued at $35,216,932 in the last ninety days. Insiders own 4.20% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.